Hair-loss information and possible hair-loss treatment at propecia.com

This site is intended only for healthcare professionals of the United States,
its territories, and Puerto Rico. Non-US residents click here.

5-Year Data

	See the results of the longest reported controlled clinical study of male pattern hair loss.

View study results.

Patient Brochure

The following patient brochure is intended to help answer your patients’ questions about PROPECIA^® (finasteride). You can view this brochure online.

To view PDF documents, you must have the Adobe Reader installed on your computer.



Indications

	PROPECIA is the first oral therapy indicated for the treatment of male pattern hair loss in MEN ONLY. Safety and efficacy were demonstrated in men, aged 18 to 41, with mild to moderate hair loss of the vertex and anterior mid-scalp area. Efficacy in bitemporal recession has not been established.

	PROPECIA is not indicated in women or children.

Contraindications

	PROPECIA is contraindicated in women when they are or may potentially be pregnant. Finasteride may cause abnormalities of the external genitalia of a male fetus of a pregnant woman.

	PROPECIA is contraindicated in patients with hypersensitivity to any component of this medication.

Warnings

	Women should not handle crushed or broken PROPECIA tablets when they are pregnant or may potentially be pregnant because of the possibility of absorption of finasteride and the subsequent potential risk to a male fetus. PROPECIA tablets are coated and will prevent contact with the active ingredient during normal handling, provided that the tablets have not been broken or crushed.


	Order Samples AAD Meetings Links

PROPECIA is a registered trademark of Merck & Co., Inc.

20850675(2)-04/08-PRP